Loomis, Sayles & Company
ITCI

Loomis, Sayles & Company’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Loomis, Sayles & Company’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-351,573
Closed -$18.9M – 1151
2015
Q4 		$18.9M Buy
351,573
+134,384
+62% +$6.78M 0.05% 306
2015
Q3 		$8.7M Buy
217,189
+198,895
+1,087% +$6.49M 0.03% 439
2015
Q2 		$584K Buy
+18,294
New +$464K ﹤0.01% 604

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Loomis, Sayles & Company's ITCI Position: Q1 2016 in Review

Loomis, Sayles & Company sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2016, closing a stake of 351,573 shares — an estimated $18.9M sold.

Loomis, Sayles & Company first reported a position in ITCI in Q2 2015 and held it in 3 quarters. The position peaked at $18.9M in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

  • Loomis, Sayles & Company reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 351,573 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $18.9M.
  • Loomis, Sayles & Company first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 3 quarters.
  • Loomis, Sayles & Company's Intra-Cellular Therapies Inc. position peaked at $18.9M in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on Loomis, Sayles & Company's 13F filing for Q1 2016, filed 13 May 2016.